MedPath

Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma

Phase 1
Completed
Conditions
Leukemia
Lymphoma
Registration Number
NCT00020111
Lead Sponsor
National Cancer Institute (NCI)
Brief Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide in treating young patients with leukemia or lymphoma.

Detailed Description

OBJECTIVES:

* Determine the toxic effects of arsenic trioxide in pediatric patients with refractory leukemia or lymphoma.

* Determine the maximum tolerated dose of this drug in this patient population.

* Determine the plasma pharmacokinetics of this drug in these patients.

OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to disease (acute promyelocytic leukemia \[APL\] vs non-APL).

* Stratum I (APL patients): Patients receive standard-dose arsenic trioxide IV over 2 hours daily 5 days a week for 4 weeks. Treatment continues every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.

* Stratum II (Non-APL patients): Cohorts of 3-6 patients receive escalating doses of arsenic trioxide (according to the stratum 1 schedule above) until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with arsenic trioxide at the recommended phase II dose.

Leukemia patients in both strata without progressive disease who have not achieved complete remission after the first 20 doses may continue to receive arsenic trioxide for 2 additional weeks.

Patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A maximum of 18 patients will be accrued for stratum I of this study within 2-3 years. A total of 3-30 patients will be accrued for stratum II of this study within 1-2 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (52)

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus

πŸ‡ΊπŸ‡Έ

Atlanta, Georgia, United States

University of Mississippi Medical Center

πŸ‡ΊπŸ‡Έ

Jackson, Mississippi, United States

Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas

πŸ‡ΊπŸ‡Έ

Dallas, Texas, United States

Children's Hospital of Philadelphia

πŸ‡ΊπŸ‡Έ

Philadelphia, Pennsylvania, United States

Children's Memorial Hospital - Chicago

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

πŸ‡ΊπŸ‡Έ

Boston, Massachusetts, United States

Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University

πŸ‡ΊπŸ‡Έ

Cleveland, Ohio, United States

MD Anderson Cancer Center at University of Texas

πŸ‡ΊπŸ‡Έ

Houston, Texas, United States

Texas Children's Cancer Center

πŸ‡ΊπŸ‡Έ

Houston, Texas, United States

Riley Children Cancer Center at Riley Hospital for Children

πŸ‡ΊπŸ‡Έ

Indianapolis, Indiana, United States

Cincinnati Children's Hospital Medical Center

πŸ‡ΊπŸ‡Έ

Cincinnati, Ohio, United States

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center

πŸ‡ΊπŸ‡Έ

Kansas City, Kansas, United States

SUNY Upstate Medical University Hospital

πŸ‡ΊπŸ‡Έ

Syracuse, New York, United States

Duke Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Durham, North Carolina, United States

University of Texas Health Science Center at San Antonio

πŸ‡ΊπŸ‡Έ

San Antonio, Texas, United States

Princess Margaret Hospital for Children

πŸ‡¦πŸ‡Ί

Perth, Western Australia, Australia

Children's Hospital of Orange County

πŸ‡ΊπŸ‡Έ

Orange, California, United States

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support

πŸ‡ΊπŸ‡Έ

Bethesda, Maryland, United States

Mayo Clinic Cancer Center

πŸ‡ΊπŸ‡Έ

Rochester, Minnesota, United States

Oklahoma University Medical Center

πŸ‡ΊπŸ‡Έ

Oklahoma City, Oklahoma, United States

Vanderbilt Children's Hospital

πŸ‡ΊπŸ‡Έ

Nashville, Tennessee, United States

Huntsman Cancer Institute at University of Utah

πŸ‡ΊπŸ‡Έ

Salt Lake City, Utah, United States

Midwest Children's Cancer Center

πŸ‡ΊπŸ‡Έ

Milwaukee, Wisconsin, United States

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

πŸ‡ΊπŸ‡Έ

Little Rock, Arkansas, United States

Children's Hospital Los Angeles

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

City of Hope Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Duarte, California, United States

Jonsson Comprehensive Cancer Center, UCLA

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

County of Los Angeles Harbor-UCLA Medical Center

πŸ‡ΊπŸ‡Έ

Torrance, California, United States

Lucile Packard Children's Hospital at Stanford University Medical Center

πŸ‡ΊπŸ‡Έ

Palo Alto, California, United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

πŸ‡ΊπŸ‡Έ

Baltimore, Maryland, United States

Floating Hospital for Children

πŸ‡ΊπŸ‡Έ

Boston, Massachusetts, United States

University of Michigan Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Ann Arbor, Michigan, United States

Cardinal Glennon Children's Hospital

πŸ‡ΊπŸ‡Έ

Saint Louis, Missouri, United States

Children's Mercy Hospital

πŸ‡ΊπŸ‡Έ

Kansas City, Missouri, United States

St. Louis Children's Hospital

πŸ‡ΊπŸ‡Έ

Saint Louis, Missouri, United States

Children's Hospital of Michigan

πŸ‡ΊπŸ‡Έ

Detroit, Michigan, United States

NYU School of Medicine's Kaplan Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Memorial Sloan-Kettering Cancer Center

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Herbert Irving Comprehensive Cancer Center at Columbia University

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Cancer Center at Hackensack University Medical Center

πŸ‡ΊπŸ‡Έ

Hackensack, New Jersey, United States

St. Jude Children's Research Hospital

πŸ‡ΊπŸ‡Έ

Memphis, Tennessee, United States

Children's Hospital of Pittsburgh

πŸ‡ΊπŸ‡Έ

Pittsburgh, Pennsylvania, United States

Cook Children's Medical Center - Fort Worth

πŸ‡ΊπŸ‡Έ

Fort Worth, Texas, United States

Children's Hospital and Regional Medical Center - Seattle

πŸ‡ΊπŸ‡Έ

Seattle, Washington, United States

University of Wisconsin Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Madison, Wisconsin, United States

Royal Children's Hospital

πŸ‡¦πŸ‡Ί

Parkville, Victoria, Australia

Hospital for Sick Children

πŸ‡¨πŸ‡¦

Toronto, Ontario, Canada

Montreal Children's Hospital at McGill University Health Center

πŸ‡¨πŸ‡¦

Montreal, Quebec, Canada

Hopital Sainte Justine

πŸ‡¨πŸ‡¦

Montreal, Quebec, Canada

Children's National Medical Center

πŸ‡ΊπŸ‡Έ

Washington, District of Columbia, United States

UCSF Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

San Francisco, California, United States

Rebecca and John Moores UCSD Cancer Center

πŸ‡ΊπŸ‡Έ

La Jolla, California, United States

Β© Copyright 2025. All Rights Reserved by MedPath